http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110759966-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-1021 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 |
| filingDate | 2019-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110759966-B |
| titleOfInvention | caspase-3 inhibitors and uses thereof |
| abstract | The invention discloses a caspase-3 inhibitor and application thereof, comprising two molecular forms: the core functional regions are respectively DMPD (aspartic acid-methionine-proline-aspartic acid) and DMLD (aspartic acid-methionine-leucine-aspartic acid) polypeptide fragments, and both ends of the DMPD polypeptide fragment are respectively chemically modified to improve the biological characteristics, the activity and the pharmaceutical property of the polypeptide. The inhibitor can be directly combined with active caspase-3 to inhibit the enzymatic activity thereof, and effectively inhibit caspase-3/PARP mediated apoptosis and apoptosis necrosis, and caspase-3/GSDME mediated cell apoptosis. Can be used for preparing anti-cell death related tool molecules or reagents, and anti-cell death or tissue organ necrosis related diseases. |
| priorityDate | 2019-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 212.